Development of vaccines against Zika virus

Gregory A. Poland, Richard B Kennedy, Inna G. Ovsyannikova, Ricardo Palacios, Paulo Lee Ho, Jorge Kalil

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Zika virus is an emerging pathogen of substantial public health concern to human beings. Although most infections are asymptomatic or present with benign, self-limited symptoms, a small percentage of patients have complications, such as congenital anomalies in the developing fetus of pregnant women infected with the virus and neurological complications (eg, Guillain-Barré syndrome). To date, there is no vaccine, antiviral drug, or other modality available to prevent or treat Zika virus infection. In this Review, we examine vaccine development efforts for Zika virus to date and research gaps in the development of candidate vaccines against Zika virus. Top research priorities should include development of a better understanding of immunity to Zika virus to establish clear correlates of protection; determination of what effect, if any, Zika vaccine-induced immune responses will have on subsequent dengue virus infection; evaluation of vaccine immunogenicity and efficacy in healthy adults and in the various subpopulations affected by Zika virus infection (children, pregnant women, women of childbearing age, and eldery people); and identification of the molecular mechanisms that underlie birth defects and neurological sequelae related to Zika virus.

Original languageEnglish (US)
JournalThe Lancet Infectious Diseases
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Vaccines
Pregnant Women
Dengue Virus
Asymptomatic Infections
Virus Diseases
Research
Antiviral Agents
Immunity
Fetus
Public Health
Zika Virus
Viruses
Zika Virus Infection

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Poland, G. A., Kennedy, R. B., Ovsyannikova, I. G., Palacios, R., Ho, P. L., & Kalil, J. (Accepted/In press). Development of vaccines against Zika virus. The Lancet Infectious Diseases. https://doi.org/10.1016/S1473-3099(18)30063-X

Development of vaccines against Zika virus. / Poland, Gregory A.; Kennedy, Richard B; Ovsyannikova, Inna G.; Palacios, Ricardo; Ho, Paulo Lee; Kalil, Jorge.

In: The Lancet Infectious Diseases, 01.01.2018.

Research output: Contribution to journalArticle

Poland, Gregory A. ; Kennedy, Richard B ; Ovsyannikova, Inna G. ; Palacios, Ricardo ; Ho, Paulo Lee ; Kalil, Jorge. / Development of vaccines against Zika virus. In: The Lancet Infectious Diseases. 2018.
@article{6b03b5d9e0b54a349cf8dd4ab3b34cfe,
title = "Development of vaccines against Zika virus",
abstract = "Zika virus is an emerging pathogen of substantial public health concern to human beings. Although most infections are asymptomatic or present with benign, self-limited symptoms, a small percentage of patients have complications, such as congenital anomalies in the developing fetus of pregnant women infected with the virus and neurological complications (eg, Guillain-Barr{\'e} syndrome). To date, there is no vaccine, antiviral drug, or other modality available to prevent or treat Zika virus infection. In this Review, we examine vaccine development efforts for Zika virus to date and research gaps in the development of candidate vaccines against Zika virus. Top research priorities should include development of a better understanding of immunity to Zika virus to establish clear correlates of protection; determination of what effect, if any, Zika vaccine-induced immune responses will have on subsequent dengue virus infection; evaluation of vaccine immunogenicity and efficacy in healthy adults and in the various subpopulations affected by Zika virus infection (children, pregnant women, women of childbearing age, and eldery people); and identification of the molecular mechanisms that underlie birth defects and neurological sequelae related to Zika virus.",
author = "Poland, {Gregory A.} and Kennedy, {Richard B} and Ovsyannikova, {Inna G.} and Ricardo Palacios and Ho, {Paulo Lee} and Jorge Kalil",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/S1473-3099(18)30063-X",
language = "English (US)",
journal = "The Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "Lancet Publishing Group",

}

TY - JOUR

T1 - Development of vaccines against Zika virus

AU - Poland, Gregory A.

AU - Kennedy, Richard B

AU - Ovsyannikova, Inna G.

AU - Palacios, Ricardo

AU - Ho, Paulo Lee

AU - Kalil, Jorge

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Zika virus is an emerging pathogen of substantial public health concern to human beings. Although most infections are asymptomatic or present with benign, self-limited symptoms, a small percentage of patients have complications, such as congenital anomalies in the developing fetus of pregnant women infected with the virus and neurological complications (eg, Guillain-Barré syndrome). To date, there is no vaccine, antiviral drug, or other modality available to prevent or treat Zika virus infection. In this Review, we examine vaccine development efforts for Zika virus to date and research gaps in the development of candidate vaccines against Zika virus. Top research priorities should include development of a better understanding of immunity to Zika virus to establish clear correlates of protection; determination of what effect, if any, Zika vaccine-induced immune responses will have on subsequent dengue virus infection; evaluation of vaccine immunogenicity and efficacy in healthy adults and in the various subpopulations affected by Zika virus infection (children, pregnant women, women of childbearing age, and eldery people); and identification of the molecular mechanisms that underlie birth defects and neurological sequelae related to Zika virus.

AB - Zika virus is an emerging pathogen of substantial public health concern to human beings. Although most infections are asymptomatic or present with benign, self-limited symptoms, a small percentage of patients have complications, such as congenital anomalies in the developing fetus of pregnant women infected with the virus and neurological complications (eg, Guillain-Barré syndrome). To date, there is no vaccine, antiviral drug, or other modality available to prevent or treat Zika virus infection. In this Review, we examine vaccine development efforts for Zika virus to date and research gaps in the development of candidate vaccines against Zika virus. Top research priorities should include development of a better understanding of immunity to Zika virus to establish clear correlates of protection; determination of what effect, if any, Zika vaccine-induced immune responses will have on subsequent dengue virus infection; evaluation of vaccine immunogenicity and efficacy in healthy adults and in the various subpopulations affected by Zika virus infection (children, pregnant women, women of childbearing age, and eldery people); and identification of the molecular mechanisms that underlie birth defects and neurological sequelae related to Zika virus.

UR - http://www.scopus.com/inward/record.url?scp=85041608916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041608916&partnerID=8YFLogxK

U2 - 10.1016/S1473-3099(18)30063-X

DO - 10.1016/S1473-3099(18)30063-X

M3 - Article

C2 - 29396004

AN - SCOPUS:85041608916

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

SN - 1473-3099

ER -